



PARTNERSHIP FORUM

No. 2  2021



EXECUTIVE SUMMARY

Digital Therapeutics: The Evolving Role of Digital Therapeutics

Given the evolving role of digital therapeutics (DTx) and the need for continued framing of ways to develop, evaluate, and increase access to these products, AMCP held a second DTx Partnership Forum on Aug. 31–Sept. 1, 2021. The group of over 40 experts included payers, pharmacy benefit managers, integrated delivery systems, health economists and analysts, patient advocates, academicians, digital therapeutic innovators, and other key managed care stakeholders convened virtually. These participants were asked to: 1) identify current marketplace challenges around use and coverage of DTx; 2) provide input to outline guiding principles for health care decision makers to assist in coverage decisions for DTx; 3) identify best practices that health plans can consider when evaluating digital therapeutics.

Areas of opportunity identified by participants include:

- **Align governance, guidance, and standards** across the DTx industry including definitions, categorization of products, and market entry requirements, and develop database and compendium resources to foster product awareness and demand.
- **Standardize evidence frameworks** to guide evaluation of DTx and assist payers with determining who should review and how, and appropriate benefit placement for unique products that might not fit exactly into the existing benefit paradigm.
- **Promote provider adoption** by addressing needs such as ease of product integration into their workflow, a clear path for reimbursement, and equity of access by acknowledging that factors including demographics and internet availability play a role.

continued on next page

WATCH FOR FOLLOW-UP

The Partnership Forum is the continuation of AMCP's efforts around DTx and the role of managed care pharmacy. Our next steps will be to:

- Publish a proceedings document on all findings and recommendations from the Partnership Forum in an upcoming issue of AMCP's *Journal of Managed Care + Specialty Pharmacy (JMCP)* and disseminate it widely to decision makers around the country.
- Host a forthcoming webinar to report these findings and recommendations.
- Finalize the guiding principles discussed during the forum.
- Review the inclusion of DTx into *AMCP Format*.
- Provide educational opportunities around DTx.
- Monitor and support policy to advance the coverage and utilization of DTx.

CONTACT INFO

675 N Washington Street | Suite 220
Alexandria, VA 22314

703 684 2600 | www.amcp.org | [@amcporg](https://twitter.com/amcporg)

AMCP | Academy of Managed Care Pharmacy

EXECUTIVE SUMMARY

- **Evolve professional expertise** of all health care stakeholders, including pharmacists, to understand the place and potential benefit of DTx in patient care, and to evaluate and manage DTx products.
- **Consider ongoing product requirements**, including ownership, security, and interoperability of the data generated, and communication of product updates including what types of updates require communication, and how and to whom these communications should be provided.

As industry thought leaders, participants also gave feedback on a set of definitions and guiding principles drafted by AMCP intended to:

- 1) Provide guidance to digital health innovators regarding the standard of evidence that will be expected to accompany DTx;
- 2) Assist payers in making informed and consistent DTx coverage decisions; and
- 3) Improve patient access and understanding of DTx value and their risks versus benefits.

Some of the primary considerations that were deliberated among the group to be included in the principles were similar to the opportunities identified such as how to categorize and standardize definitions for the many types of DTx products, the role of the FDA or other regulatory

bodies in approval or market authorization of DTx, the role of P&T committees or equivalent bodies in the evaluation of DTx products, the expectation that evidence demonstrates that a DTx product improves quality of care, and the need for communicating impactful product updates to payers, health care decision makers, and patients.

“*The diversity of participant backgrounds provided an excellent platform to not only discuss the challenges, but also begin the process of reaching solutions and practical next steps.*”

Astha Chopra
Magellan

THANK YOU TO OUR 2021 AMCP PARTNERSHIP FORUM SPONSORS

